Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating for Liquidia (NASDAQ:LQDA) and maintained a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:17 am

Needham analyst Serge Belanger has reiterated a Buy rating on Liquidia (NASDAQ:LQDA) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 4:02 pm

Liquidia has filed a lawsuit challenging the FDA's decision to grant 3-year exclusivity to Tyvaso DPI, delaying the final approval of its own drug, YUTREPIA, until May 2025.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 10:05 am

Jim Cramer praised PayPal's CEO and recommended buying Flutter Entertainment due to its strong performance and potential growth with the football season. He expressed skepticism about Liquidia Corporation and Crown Castle, and advised selling AST SpaceMobile.

Portfolio Pulse from Avi Kapoor

August 21, 2024 | 1:23 pm

Liquidia Corporation (NASDAQ:LQDA) received tentative FDA approval for YUTREPIA, a treatment for pulmonary hypertension, but faces regulatory exclusivity challenges from United Therapeutics' Tyvaso DPI. Liquidia's stock fell 30.6% following the news, and analysts have lowered their price targets while maintaining Buy ratings.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 12:15 pm

Top Wall Street analysts have updated their price targets and ratings for several companies, including Palo Alto Networks, Fabrinet, Estée Lauder, Liquidia, Snowflake, ZIM Integrated Shipping, Globant, Stride, BioMarin Pharmaceutical, and Hyatt Hotels. These changes reflect varying expectations for stock performance, with some companies seeing upgrades and others downgrades.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 11:53 am

BTIG analyst Julian Harrison maintains a Buy rating on Liquidia (NASDAQ:LQDA) but lowers the price target from $29 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 11:47 am

B of A Securities has maintained its Buy rating on Liquidia (NASDAQ:LQDA) but has slightly lowered the price target from $24 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 11:29 am

HC Wainwright & Co. has maintained a Buy rating on Liquidia (NASDAQ:LQDA) but lowered the price target from $32 to $29.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 10:48 am

U.S. stocks rose with the Nasdaq gaining 150 points. ZIM Integrated Shipping Services reported strong Q2 results, boosting its stock. Alzamend Neuro surged 474% after announcing a partnership for a PTSD study. Sonder Holdings rose 98% following a licensing deal with Marriott and securing $146M in liquidity. Liquidia Corporation fell 29% after FDA's tentative approval of YUTREPIA. Theriva Biologics and Cingulate Inc. also saw significant declines.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 6:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.